^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Mucosal Melanoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
Published date:
07/05/2021
Excerpt:
A total of 206 patients were assessed, including 92 cutaneous melanoma patients with 12 NRAS mutations and 114 noncutaneous melanoma patients with 21 NRAS mutations….NRAS wild-type melanoma included patients with BRAF or KIT mutations….In the noncutaneous melanoma population, 12 from 114 patients had NRAS mutations, including 9 acral and 3 mucosal melanoma patients. The response rates of NRAS mutant patients and NRAS wild-type patients were 0% and 13.7% (P=0.356), and the DCRs were 33.3% and 51.0% (P=0.247), respectively...
DOI:
10.3389/fimmu.2021.691032
Trial ID:
